US 7959566

I'll search for authoritative information on this patent number and any 2026 appellate dockets.

Let me try to retrieve the actual claim text, since the provided copy was truncated mid-description.

US 7,959,566 B2 — Summary

Important scope note up front: I searched for this exact identifier (7959566) and did not find any Federal Circuit 2026 docket naming US 7,959,566. The 2026 CAFC material returned by search involved unrelated matters (Contour IP v. GoPro, No. 2026-2012; Saha Thai Steel Pipe v. US, No. 2026-1566; In re United States, No. 2026-144, etc.). I therefore report no authoritative evidence of a CAFC 2026 appeal involving this patent, as opposed to asserting there is none. All bibliographic and claim data below comes from the patent document itself and third‑party patent databases, not from a live USPTO docket query.

Bibliographic data

Continuation chain (from the specification's Cross‑Reference section, verbatim order):
11/437,551 (the '566 patent) ← 11/028,144 (now US 7,141,018) ← 10/762,880 (US 6,869,399) ← 10/383,275 (US 6,755,784) ← 09/965,155 (US 6,561,977) ← 09/694,217 (US 6,315,720). The '720 patent is the parent whose Jepson‑format claims and PTAB/Federal Circuit history are most often discussed in the literature; the '566 patent is a different, later‑issued claim set.

Litigation flags on the Google Patents record: two US cases in the District of New Jersey — 2:15‑cv‑00697 and 2:18‑cv‑13477 — plus a Darts‑IP "first worldwide family litigation" link (family 24787895). Note these are litigation database entries about the patent family generally; I cannot confirm from these sources which specific claims of the '566 patent were at issue.

Abstract (as printed)

"Methods for delivering a drug to a patients in need of the drug, while restricting access to the drug by patients for whom the drug may be contraindicated are disclosed. The methods are of the type in which prescriptions for the drug are filled by a pharmacy only after a computer readable storage medium has been consulted to retrieve a prescription approval code. Embodiments are provided wherein the patients are assigned to risk groups based upon the risk that taking the drug will lead to an adverse side effect, and certain additional information, such as periodic surveys and diagnostic tests probative of the ongoing risk of the side effect developing are obtained before prescriptions for the drug are approved."

Independent claim (plain language)

The '566 patent has one independent claim — claim 1; claims 2–5 depend from it.

Claim 1 (method of treating a male ENL patient with thalidomide using an approval-code gate):

A method of treating a male patient suffering from erythema nodosum leprosum (ENL) with thalidomide, in which a pharmacy may fill the prescription only after it has retrieved a prescription approval code. The recited steps are:

• (a) registering the prescriber and the pharmacy with the thalidomide distributor via a non‑transitory computer readable storage medium;
• (b) determining whether the patient can understand and carry out instructions;
• (c) if so, giving the patient verbal and written warnings of the hazard of taking thalidomide and of fetal exposure;
• (d) also giving verbal and written warnings of possible contraception failure and of the need for barrier contraception when having intercourse with women of childbearing potential;
• (e) obtaining the patient's acknowledgement of those warnings;
• (f) the prescriber gives the prescription to the patient;
• (g) registering the patient with the distributor via a non‑transitory computer readable storage medium;
• (h) upon the acknowledgement and registrations, generating the prescription approval code, which the pharmacy retrieves from a medium before filling; and
• (i) upon retrieval, administering thalidomide to the patient.

Plain‑language takeaway: it is a step‑ordered, closed‑loop "restricted distribution" workflow for thalidomide in male ENL patients — competency check → dual (verbal + written) risk counseling including contraception/fetal‑exposure warnings → patient acknowledgement → prescriber, pharmacy and patient registration in a database → computer‑generated approval code that the pharmacy must retrieve → dispensing/administering.

Dependent claims:

• Claim 2 — the acknowledgement must cover one or more of a specific list: no thalidomide if unprotected sex cannot be avoided; understanding of potential birth defects; having been advised of barrier contraception; obligation to inform the prescriber if a partner is or may be pregnant; no sharing the drug; having read the brochure/viewed the film; no donating semen or blood; all inquiries answered; and understanding that survey/patient‑registry participation is required.
• Claim 3 — also warn the patient, before code generation, of non‑teratogenic side effects.
• Claim 4 — obtain a written authorization from the prescriber before code generation.
• Claim 5 — the acknowledgement is a written informed consent.

Claim‑construction note (analytic, not from the patent text): the specification describes risk‑group assignment, periodic surveys, serum pregnancy testing and diagnostic testing at length, but the '566 claims do not recite risk groups, surveys, or diagnostic tests. Claim 1 is instead limited to a male patient with ENL and to thalidomide. The sibling patent US 8,315,886 (same inventors/assignee, application 12/966,261) contains the broader parallel claim directed to a "male patient having a disease or condition responsive to a teratogenic drug." The '566 claim 1 is therefore the narrower, thalidomide/ENL‑specific branch of the family. In the New Jersey REMS litigation, the parties disputed the construction of "prescription approval code" and "computer readable storage medium" (Celgene urging a centralized‑database reading) — that construction dispute is on the record in Celgene's NJ filings, but I have not verified which patent numbers that particular brief addressed.

Data provenance and uncertainty

• Patent text, abstract, inventors, assignee, dates, continuation chain, expiration and NJ litigation links: Google Patents, https://patents.google.com/patent/US7959566/en; printed patent PDF at https://patentimages.storage.googleapis.com/1a/20/d7/8b8340de0cfd35/US7959566.pdf (front page and "5 Claims, No Drawings").
• Claim 1 and dependent claims 2–5 text: DrugPatentWatch, https://www.drugpatentwatch.com/p/patent-claims/[7959566](/patent/7959566) and https://www.drugpatentwatch.com/p/patent-exob/7959566 (last updated 2026), which match the front‑page claim count of 5. Caveat: a court filing in the record quoted a seven‑claim set with different claim 5–7 text; that excerpt belongs to US 8,626,531, not to the '566 patent — do not conflate them.
• Unverified / cannot confirm: (i) whether any 2026 Federal Circuit appeal involves the '566 patent specifically — none was found; (ii) current real‑party ownership beyond the Google Patents "Celgene Corp" entry; (iii) whether the '566 patent's claims were themselves subject to any IPR (the well‑known Celgene IPRs, e.g. IPR2015‑01092 and IPR2015‑01098/01102/01103, challenged the '501 and '720 patents, not this one, on the record I retrieved).
• I did not and cannot auto‑correct any identifier; 7959566 was searched and reported literally.

I'll research litigation involving US patent 7959566. Let me run several targeted searches.

Let me search for more specific cases and outcomes.

Let me check the specific patent's litigation record and verify which cases assert the '566 patent.

Litigation Involving U.S. Patent No. 7,959,566

Important preliminary note on scope: I searched litigation databases (Unified Patents portal, DrugPatentWatch, Justia Dockets, CourtListener/RECAP, Darts-IP family data reproduced on Google Patents, and Celgene/competitor antitrust complaints) for the exact number 7,959,566. Below are the matters I could tie specifically to the '566 patent. I flag explicitly where I could not independently confirm that the '566 patent was among the patents asserted.

The '566 patent (Celgene Corp.; inventors Bruce A. Williams and Joseph K. Kaminski; issued June 14, 2011; statutory term adjusted/expired March 11, 2021) is one of Celgene's so-called "distribution method" / REMS (S.T.E.P.S.) patents — part of the family including U.S. 6,315,720; 6,561,977; 6,755,784; 6,869,399; 7,141,018; 7,230,012; 8,315,886; and 8,626,531. Nearly all the enforcement activity is Hatch-Waxman/ANDA litigation over generic thalidomide (Thalomid) and lenalidomide (Revlimid).

1. Celgene Corporation v. Hikma Pharmaceuticals International Limited (and related Hikma/West-Ward entities)

• Plaintiff: Celgene Corporation
• Defendants: Hikma Pharmaceuticals International Limited (caption later amended; Hikma Pharmaceuticals USA, Inc. and West-Ward Pharmaceuticals International Limited also appeared)
• Jurisdiction: U.S. District Court for the District of New Jersey (Newark), Judge Susan D. Wigenton; Magistrate Judge Leda D. Wettre
• Case No.: 2:18-cv-13477
• Filing date: August 31, 2018
• Nature: ANDA patent infringement under 35 U.S.C. § 271(e)(2) over West-Ward's proposed generic thalidomide (ANDA No. 211947, 50/100/150/200 mg). The complaint expressly asserts nine Celgene patents, including "the '566 patent" (7,959,566), together with the '720, '977, '784, '399, '018, '012, '886, and '531 patents.
• Outcome / status: Terminated September 18, 2019. No reported judgment; the termination (coinciding with Bristol-Myers Squibb's acquisition of Celgene) is consistent with a settlement/voluntary dismissal. I did not locate a public opinion or consent judgment in this docket.
• Sources: DrugPatentWatch litigation page for 2:18-cv-13477 (patent list including 7,959,566); Unified Patents litigation portal page for 2:18-cv-13477; complaint-analysis page quoting the '566 patent (col. 18:1-55).

2. Celgene Corporation et al. v. Lannett Holdings, Inc. et al.

• Plaintiff: Celgene Corporation
• Defendant: Lannett Holdings, Inc. (and affiliates)
• Jurisdiction: U.S. District Court for the District of New Jersey, Judge Susan D. Wigenton; Magistrate Judge Leda D. Wettre
• Case No.: 2:15-cv-00697
• Filing date: January 30, 2015
• Nature: ANDA patent infringement over generic thalidomide (Lannett ANDA No. 206601); Celgene asserted fifteen patents.
• Outcome / status: Settled. On October 10, 2017, the parties stipulated that Lannett would convert its Paragraph IV certification on the '745 patent to a Paragraph III certification and Celgene would dismiss its infringement claims. On October 30, 2017, Celgene and Lannett announced a settlement and license agreement permitting Lannett to market generic thalidomide as of August 1, 2019.
• Confidence caveat: Google Patents' "family has litigation" data for 7,959,566 links this case to the '566 patent family (the other linked New Jersey case being 2:18-cv-13477 above). However, I could not confirm from the sources retrieved that the '566 patent was among the fifteen patents specifically asserted in the Lannett complaint. Treat the '566-connection here as probable but not verified.

Related matters that reference the '566 patent family but do not assert the '566 patent as a cause of action

These are antitrust cases (not patent infringement suits); they repeatedly reference Celgene's "Distribution Method"/REMS patents (the same family as the '566 patent) as alleged improperly listed Orange Book patents and as the basis for alleged "sham" patent litigation:

• In re Thalomid and Revlimid Purchaser Antitrust Litigation (consolidated payor/insurer class actions; D.N.J.).
• The Cigna Group v. Celgene Corporation, No. 1:25-cv-05237 (E.D. Pa., filed June 24, 2025) (and predecessor Cigna Corp. v. Celgene Corp., No. 2:21-cv-00090, E.D. Pa.).
• Molina Healthcare and Humana complaints (thalidomide/lenalidomide pay-for-delay allegations).

In these pleadings the "Distribution Method Patents" are described as a family that includes the '720, '977, '784, '399, '018, '012, '566, '886, and '531 patents, and the alleged sham patent suits against Barr, Lannett, Natco, Dr. Reddy's, Zydus, Lotus/Alvogen, Cipla, and Sun are discussed. They are cited for antitrust context, not as '566 infringement counts.

Matters I checked that do not involve the '566 patent

• Celgene Corp. v. Barr Laboratories, Inc., Nos. 2:07-cv-00286; 2:07-cv-04050; 2:07-cv-05485; 2:08-cv-03357 (D.N.J.) — filed 2007–2008, before the '566 patent issued (June 2011); the asserted patents were U.S. 5,629,327; 6,235,756; and 7,435,745. All claims were dismissed after Barr withdrew its thalidomide ANDA (May 2010).
• Celgene Corp. v. Natco Pharma Ltd. et al., No. 2:10-cv-05197 (D.N.J.) — filed 2010, also before '566 issued.
• Celgene Corp. v. Apotex Inc., No. 2:19-cv-13994 (D.N.J.) — patent list does not include 7,959,566.

IPR / PTAB

I am aware of inter partes reviews against the closely related '501 and '720 patents (e.g., Celgene Corp. v. Peter / Coalition for Affordable Drugs; the '720 claims were held unpatentable, spawning the Supreme Court cert petition in Celgene Corp. v. Peter, No. 19-1074). I could not confirm any IPR petition specifically against U.S. 7,959,566, so I am not reporting one.

Bottom line

Based on the sources I could retrieve, the principal patent-infringement litigation specifically asserting U.S. 7,959,566 is Celgene Corp. v. Hikma Pharmaceuticals (and West-Ward), D.N.J. No. 2:18-cv-13477, filed August 31, 2018 and terminated September 18, 2019 (apparently by settlement/dismissal). The Celgene v. Lannett case (2:15-cv-00697, settled in 2017) is linked to the '566 family by Google Patents' litigation data, but I could not verify the '566 patent among its asserted patents. No case resulted in a judgment on the merits of the '566 patent that I could locate.

Caveat: I reached my tool-call limit before I could open the DrugPatentWatch and Darts-IP pages dedicated solely to patent 7,959,566 and confirm the complete national docket list. The list above reflects what I verified from the retrievable sources; a final confirmation should be run against PACER (D.N.J.) and the Unified Patents / Darts-IP pages for patent 7,959,566 to catch any additional short-lived ANDA suits (e.g., against Lotus/Alvogen, Dr. Reddy's, Cipla, or Sun) in which the '566 patent may have been listed.

I'll start by verifying the canonical list and checking for any PTAB activity the ODP may not have indexed.

No '566-specific IPRs surfaced yet. Let me dig into the Celgene REMS-patent IPR cluster and the litigation/PTAB tracker pages to confirm.

The '566 patent appears only as a family-tree exhibit in IPR2015-01103 (which targets the '720 patent). Let me confirm no proceeding names '566 as the challenged patent.

Bottom line up front

I ran the structured ODP block you supplied and independently searched PTAB/Federal Circuit materials to look for anything the ODP ingest might have missed. I found no AIA trial proceeding in which US 7,959,566 was the challenged patent. The only place the '566 even appears in PTAB papers is as a patent-family-tree exhibit (Exhibit 2041) in IPR2015-01103, which targets a different Celgene patent (U.S. 6,315,720). That is a cite, not a challenge.

Proceedings overview

Total AIA trial proceedings on file for US 7,959,566: 0 (0 active / 0 claims invalidated / 0 claims sustained / 0 settled / 0 institution denied) — the patent has never been the subject of an IPR, PGR, or CBM at the PTAB, so its posture is neither "hardened by surviving IPRs" nor "gutted by cancellation"; it is PTAB-untested, and the defensive value of the absence depends entirely on the fact that Celgene's sibling REMS patents in the same specification family were knocked out in IPRs that never named the '566.

Caveat on sourcing: the ODP list is empty, and my web searches corroborate rather than contradict that. I could not locate a single petition, institution decision, or FWD naming 7,959,566 as the subject patent. If a petition was filed in the last few months it may not be indexed, but there is no affirmative evidence of one.

Why there is nothing to report (and the near-miss worth knowing)

The '566 is a method-of-treatment claim (claim 1: "A method of treating a male patient, suffering from erythema nodosum leprosum, with thalidomide…"), one of the "Williams family" of Celgene REMS/distribution patents. The family and its neighbors were heavily attacked — but not this patent:

• IPR2015-01092, -01096, -01102, -01103 — Coalition for Affordable Drugs VI LLC v. Celgene Corp. (the Kyle Bass "reverse troll" campaign). These challenged U.S. 6,045,501 and U.S. 6,315,720 — not the '566. PTAB instituted 2015-10-27; FWDs issued 2016-10-26 holding the '501 and '720 claims unpatentable primarily for obviousness; Celgene's rehearing request was denied as to the '501 and granted in part as to one claim of the '720 (2017-09-08). Celgene appealed: Celgene Corp. v. Peter, Nos. 2018-1167, -1168, -1169 (Fed. Cir.), argued 2018-06-03, raising a Fifth Amendment takings challenge to retroactive IPR of pre-AIA patents.
• IPR2015-01103, Exhibit 2041 (Celgene's own exhibit, an "IPNav patent family tree") lists U.S. 7,959,566 / App. 11/437,551 / filed 05/19/2006 as a family member. This is the source of any search hit pairing "'566" with "IPR2015-01103." It is not a challenged patent in that proceeding.
• IPR2017 proceedings on the '788, '536, and '229 patents (instituted 2017-10-10) and a denied IPR on the '260 patent (2017-10-11) — again, other patents, not the '566.
• In the antitrust MDL, plaintiffs characterized U.S. 7,720 / '977 / '784 / '399 as invalidated by the PTAB and alleged the '018, '566, and others were "not sufficiently distinct" from them (infectious unenforceability theory). But the court expressly declined to reach the Walker Process / unenforceability challenges as to the '399, '018, and '566 patents. So no PTAB adjudication of the '566 exists even indirectly.

The real record on the '566 is district-court, not PTAB

• The '566 was Orange-Book-listed for THALOMID and asserted in Hatch-Waxman litigation in D.N.J., including Celgene Corp. v. Lannett Holdings, Inc., No. 2:15-cv-00697 and a later 2018 action (No. 2:18-cv-13477). Lannett's 2014-12-18 Paragraph IV notice certified against the '566 (among ~17 patents); the case settled 2017-10-24 (stipulated dismissal 2017-10-30), with Lannett licensed to sell generic thalidomide beginning 2019-08-01. Later Paragraph IV filers (e.g., West-Ward, notice dated 2018-07-19) likewise certified against the '566.
• Status/term: Google Patents shows the patent expired — fee related, adjusted expiration 2021-03-11; the antitrust MDL chart lists a 2020-10-23 expiry. Either way, the patent has expired as of today (2026-10-01), so any live dispute is past damages only.

Strategic summary

Claim status (all claims UNTESTED at the PTAB). Claims 1–5 of the '566 — the only claims I can verify from the public record (claim 1 independent; claims 2–5 dependent) — have never been construed or cancelled by the Board. That is the whole story: there is no FWD to point a court to, no claim held unpatentable, and no claim affirmatively "sustained." Contrast with the family: the '720 (the '566's ultimate parent via the continuation chain 09/694,217 → 09/965,155 → 10/383,275 → 10/762,880 → 11/028,144 → 11/437,551) and the '977, '784, and '399 were invalidated, and the '566 shares the same specification and disclosure. A defendant should read that as the strongest signal available: the art that killed the ancestors is the art to run against the '566.

Estoppel landscape. Because no IPR/PGR/CBM was ever instituted against the '566, § 315(e)(2) estoppel is a non-issue — neither petitioner-side estoppel nor the Board's claim-construction record constrains anyone. The complete universe of § 102/§ 103 art, plus § 101 and § 112 defenses, remains fully available to a district-court defendant (subject only to the ordinary § 282 burdens and any inter partes estoppel arising from other Celgene patents if a defendant was a real party in interest in the CFAD or Apotex IPRs — those estoppels attach patent-by-patent, not to the '566). Practically, this means a defendant retains maximum freedom to run invalidity, and the patent owner cannot point to a PTAB victory to short-circuit the challenge.

Pattern signals. The Bass/CFAD campaign and the later Apotex-led REMS IPRs show Celgene's REMS portfolio was a magnet for PTAB attacks — yet nobody petitioned on the '566. Explanations worth weighing: (a) the '566 is a narrow, thalidomide/ENL-specific method-of-treatment claim, harder to invalidate with the general REMS prior art that worked against the broad '720 pre-screening claims; (b) generics preferred Hatch-Waxman + settlement leverage; and (c) the '566 expires/expired around 2020–2021, making an IPR economically pointless by the time the AIA petitions matured. There is no defensive aggregator (Unified Patents, RPX) in the chain for this patent — the petitions that do exist came from a hedge-fund-backed coalition and a generic competitor. Celgene did appeal the adverse FWDs aggressively (Celgene v. Peter) but did not, and had no occasion to, defend the '566 at the PTAB.

Recommended next steps

1. Do not overstate the absence. If you are drafting a defensive memo or an IPR petition, say plainly: no AIA trial proceedings exist for 7,959,566; the ODP list is empty and my searches found none. Do not let anyone assume a cancelled claim. The proper framing is "untested," not "invalidated" — an assertion built on "the PTAB killed claim 1" would be wrong for this patent number.
2. The patent is expired (≈2020-10-23 / adjusted 2021-03-11). Verify the exact term and any PTA/terminal disclaimer against the USPTO PatentCenter record before relying on expiry; if expired, your exposure is limited to pre-expiry past damages within the § 286 look-back, and an IPR would likely be dismissed as moot.
3. Mine the family kill-shots. The CFAD FWDs invalidating the '720 (and the rulings on the '977, '784, '399) are the best free roadmap. Pull the FWDs from the USPTO PTAB Decisions page (https://www.uspto.gov/patents/ptab/decisions) and PTAB E2E (https://ptacts.uspto.gov/ptabweb), and the Celgene v. Peter briefs/opinion via CourtListener (https://www.courtlistener.com/). Reuse their obviousness rationale — remember these are grounds raised against other patents, so § 315(e)(2) estoppel does not bar you from using the same art against the '566.
4. Confirm the district-court posture. The '566 was litigated, not tried, in D.N.J. (Lannett, No. 2:15-cv-00697; 2018 actions including No. 2:18-cv-13477), and all known actions settled before judgment. Check the docket for any consent judgment, license, or invalidity holding that could independently bind you.
5. If a fresh petition ever surfaces, the trial-stage clock is statutory: institution decision due within ~6 months of filing, and FWD within 12 months of institution (§ 316(a)(11)). Right now, though, the correct answer to "what PTAB proceedings exist on the '566?" is: none.

If you want, I can pull the CFAD FWD PDFs for the '720 and the '977/'784/'399 rulings and extract the specific prior-art combinations so you can test them against claims 1–5 of the '566.

I'll research the assignment record and ownership chain for US 7959566.

Let me dig into the specific assignment records and post-issuance chain.

Ownership Reconstruction — US 7,959,566 B2

Scope note / method. I could not execute a live, interactive query against the USPTO Assignment Center (assignmentcenter.uspto.gov) — it is a JavaScript application that does not return record data to a text fetch, and my search budget for this session ran out before I could exhaust the legacy mirror. What follows is therefore built from primary-source reproductions of the USPTO recordation documents (a sworn court exhibit bundle containing the actual Notice of Recordation of Assignment Document, and Celgene's own PTAB mandatory notice), cross-checked against Google Patents legal events, the litigation record, and SEC/press material. Where I could not verify something directly, I say so rather than filling the gap. Treat reel/frame values below as verified only to the extent stated.

Inventors

Addresses are taken verbatim from the assignment instrument reproduced in the record ("we Bruce A. Williams and Joseph K. Kaminski … residing respectively at 37 Winding Way, Flemington, New Jersey 08822 and 20 Kalan Farm Road, Hampton, New Jersey 08827").

Employer note (honesty flag): Neither inventor is described as a "Celgene employee" on the face of the patent. Employment is a reasonable inference — the invention is the S.T.E.P.S.® (System for Thalidomide Education and Prescribing Safety) distribution method, which is Celgene's proprietary thalidomide program, both inventors resided in New Jersey near Celgene's Warren/Summit, NJ facilities, and both assigned to Celgene for nominal consideration. I would characterize this as high-confidence inference, not a documented fact from the sources I retrieved.

Unusual patterns: None detected. There is no evidence of inventors departing the assignee within 12 months of filing, and no fire-sale precursor. Both inventors remained the sole named inventors across the entire continuation chain (’720 → ’977 → ’784 → ’399 → ’018 → ’566 → ’631), which is the opposite of the churn pattern that precedes a portfolio sale.

Original assignee

Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059, a corporation of Delaware (later Summit, NJ 07901). Named on the issued patent's face; current assignee of record per Google Patents.

• Primary line of business: Integrated biopharmaceutical company (oncology, immunology/inflammation). At all relevant times an operating company, not a holding or licensing vehicle.
• Product embodying the claims: Yes — directly. The claims recite the computer-readable-medium-gated prescription approval workflow. Celgene commercialized exactly this under THALOMID® (thalidomide) via S.T.E.P.S.® and later extended the same REMS architecture to REVLIMID® (lenalidomide) via RevAssist/REMS. This is not a paper patent — it is the regulatory-distribution backbone for two marketed drugs.
• Current status: Operating, and acquired. Celgene remained an independent NYSE-listed company (CELG) through 2019. On 2019-11-20 Bristol-Myers Squibb completed a ~$74B acquisition under which "Celgene became a wholly owned subsidiary of Bristol-Myers Squibb Company." Celgene Corporation survives as a BMS subsidiary. No Chapter 7/11 filing.

Note: this patent family is also cited in Celgene's own inbound cross-references to U.S. Pat. No. 6,045,501 (Elsayed et al.) — i.e., Celgene built on an earlier third party's REMS patent rather than acquiring an NPE portfolio.

Assignment timeline

The patent is the sixth link in an unbroken continuation chain originating in application 09/694,217 (filed 2000-10-23). Consistent with standard practice, Celgene's prosecution counsel re-recorded the same inventor→company assignment against each new continuation rather than executing fresh transfers. There is no post-issuance assignment in the chain.

1. Executed 2001-01-05 / recorded 2001-01-05 — Reel 11469 / Frame 0882

• Conveyance: Assignment
• Assignor: Bruce A. Williams; Joseph K. Kaminski (joint inventors)
• Assignee: Celgene Corporation, 7 Powder Horn Drive, Warren, NJ 07059
• Correspondent: Not independently verified for this entry (I did not retrieve the underlying recordation notice). Cited in Coalition for Affordable Drugs VI LLC v. Celgene, IPR2015-01103, Paper 6 (Mandatory Notices, 2015-05-14): "Celgene owns by assignment the entire right, title, and interest … by virtue of an Assignment of rights from the inventors, Bruce A. Williams and Joseph K. Kaminski. The Assignment was recorded with the United States Patent and Trademark Office on January 5, 2001, at Reel 11469, Frame 882."
• Context: Original capture of the founding S.T.E.P.S. invention by the operating company. Consideration recited as One Dollar ($1.00) plus other good and valuable consideration — an inventor-employment-style assignment, not an arm's-length purchase.

2. Executed 2001-01-05 (document date) / recorded 2003-04-23 — Reel 013982 / Frame 0697

• Conveyance: Assignment (re-recording of the same inventor→Celgene grant against continuation application 10/383,275, filed 2003-03-07)
• Assignor: Williams, Bruce A.; Kaminski, Joseph K.
• Assignee: Celgene Corporation, 7 Powder Horn Drive, Warren, New Jersey 07059
• Correspondent: Woodcock Washburn LLP — Stephen C. Timmins, One Liberty Place, 46th Floor, Philadelphia, PA 19103-7301. One appearance only in this chain; no recurrence as an NPE recording agent is documented, and Woodcock Washburn was a mainstream general-practice IP firm (later absorbed into BakerHostetler). Not flagged as a repeat-player NPE correspondent — a single appearance by a general prosecution firm is not a finding under the stated rule.
• Context: Administrative housekeeping — Celgene's outside prosecution counsel propagating the original assignment onto each continuation so the chain of title tracked the live application. US 7,959,566 (application 11/437,551) is a descendant of this same chain.
• Caveat: the recordation notice in the exhibit bundle lists serial number 10383275 and also carries a docket marker "CELG-0508"; the exhibit's OCR interleaves pages from more than one Celgene docket, so I flag the docket attribution as uncertain while the reel/frame, parties, DOC DATE and correspondent are legible and consistent.

3. No further recorded assignment. Google Patents' legal-events ledger for US 7,959,566 shows only: application filed by Celgene Corp (2006-05-19); priority to 11/437,551; publication US20060224052A1 (2006-10-05); grant 2011-06-14; and adjusted expiration 2021-03-11. There is no reassignment, security agreement, license, release, merger or change-of-name event in the ledger. The 2019-11-20 BMS acquisition of Celgene was not recorded as an assignment against this patent — expected, since Celgene survived as a wholly owned subsidiary and title did not move. Current assignee of record therefore remains Celgene Corporation.

Bottom line: this is a two-entry chain, both entries being the same inventor assignment recorded against successive applications. The patent never left the original operating-company assignee.

Timeline diagram

timeline
    title Ownership of US 7959566
    2000 : Priority application filed
    2001 : Inventors assign to Celgene Corp
         : Recorded Reel 11469 Frame 0882
    2003 : Re-recorded against continuation filing
         : Recorded Reel 013982 Frame 0697
    2006 : Application 11 437 551 filed
    2011 : US 7959566 granted
         : Assignee of record still Celgene
    2015 : Celgene sues generic makers in D N J
    2018 : Further Celgene infringement suits filed
    2019 : Celgene becomes a BMS subsidiary
    2021 : Patent term adjusted expiration date

NPE / troll-pattern signals

Verdict

Operating-company assertion

Celgene Corporation — the original and still-current assignee of record (Reel 11469/0882 and Reel 013982/0697, both executed 2001-01-05) — is a New Jersey–based commercial biopharmaceutical manufacturer that shipped, and still ships through its Bristol-Myers Squibb parent, the very products (THALOMID® under S.T.E.P.S.®; REVLIMID® under RevAssist) whose distribution is governed by the claimed methods. It asserted this patent in its own name against actual generic competitors in the District of New Jersey (e.g. 2:15-cv-00697; 2:18-cv-13477; Celgene v. Dr. Reddy's), and was itself the defendant in REMS-based antitrust actions brought by United HealthCare Services and Blue Cross Blue Shield Association. There is no shell-entity transfer, no known asserter, no cascading LLC chain, and no pre-litigation transfer — the chain is a single inventor-to-company assignment re-recorded against successive continuations. Celgene is frequently criticized for patent thickets, REMS-based exclusivity and drug pricing (it drew Kyle Bass's Coalition for Affordable Drugs IPRs and congressional attention during the BMS deal), but criticism of an operating pharmaceutical company's exclusivity strategy is not NPE status under any of the eight signals tested.

Assumption to respect: the 2019-11-20 BMS/Celgene merger is not reflected as a recorded assignment against this patent in the sources I retrieved; if a merger or change-of-name record was later filed, it would name Bristol-Myers Squibb Company or a BMS subsidiary as assignee, which would not change the verdict.

Verify directly at:

• https://assignment.uspto.gov/patent/index.html (search patent number 7959566; also search application 11437551, and the ancestor serials 09694217, 10383275, 10028144, 10762880, 09965155 to see the full re-recording sequence)
• https://assignmentcenter.uspto.gov/
• Google Patents legal events: https://patents.google.com/patent/US7959566/en
• Corroborating primary source for the 2001 recording: IPR2015-01103, Paper 6 (Mandatory Notices by Celgene Corporation, 2015-05-14) — https://www.docketalarm.com/cases/PTAB/IPR2015-01103/Inter_Partes_Review_of_U.S._Pat._6315720/05-14-2015-Patent_Owner/Notice-6-Related_Matters/
• Reproduction of the USPTO Notice of Recordation, Reel 013982/0697: https://storage.courtlistener.com/recap/gov.uscourts.njd.[348812](/patent/348812)/gov.uscourts.njd.348812.250.30.pdf
• Assertion/defensive directories checked: Unified Patents litigation portal (https://portal.unifiedpatents.com/litigation/New%20Jersey%20District%20Court/case/2%3A18-cv-13477)

I'll search for the specific patent and its cited prior art references.

Let me retrieve the specific citation list from the patent's Google Patents record.

Let me try to retrieve the citation table directly from the patent databases.

Prior-Art Analysis — US 7,959,566 B2

Important limitation stated up front: I was not able to retrieve the complete "Patent Citations" / "References Cited" table (the front‑page examiner citations) for US 7,959,566 B2. The authoritative Google Patents text supplied for this patent (https://patents.google.com/patent/US7959566/en) contains the abstract, description, classifications and a definition list, but the fetched version omits the "References Cited" section that appears on the printed front page of the PDF. My web searches for the citation table itself returned the patent‑family pages and litigation PDFs, not the enumeration of examiner‑cited references. I therefore cannot give you an exhaustive, certified list of every cited reference. What follows is the prior art that is documented in the record I was able to retrieve, with the source for each. I flag the gaps explicitly rather than filling them by inference.

Also note: I could not run a direct USPTO PatentCenter/Patent Full‑Text query; my tooling is live web search only. Consistent with the standing rule, I searched 7959566 literally and report only results for that number.

1. Prior art identified from the patent's own specification (highest confidence)

These references are named in the authoritative patent text itself, so their citation status is certain.

Note on the continuation chain: The specification's Cross‑Reference section lists 11/028,144 (US 7,141,018), 10/762,880 (US 6,869,399), 10/383,275 (US 6,755,784), 09/965,155 (US 6,561,977) and 09/694,217 (US 6,315,720). These are related family members, not prior art to the '566 patent (they share the Oct. 23, 2000 priority), so they are properly excluded from a § 102 analysis even though they may appear in a "related applications" list.

2. Prior art asserted in the Celgene/Thalomid litigation record (medium confidence)

The antitrust and patent‑misuse filings surfaced in search — in particular the Celgene antitrust complaint (infojustice.org/wp-content/uploads/2017/07/Celgene-Antitrust-Complaint.pdf and the parallel CourtListener filing, D.N.J. 2:15‑cv‑00697 family) — expressly allege that the following were material prior art to the "Distribution Method Patents" (the family that includes the '501, '720 and '886 patents) and were not disclosed to the USPTO:

Caveat: These references are pleaded in the litigation as prior art to the family generally; the filings do not specifically pinpoint which claims of the '566 patent (as opposed to the '501/'720/'886 patents) they anticipate, and the allegations are advocacy, not adjudicated findings. I present them as asserted prior art, not as verified § 102 art against claim 1.

3. Other U.S. patents in the same commercial/technical space (lower confidence — retrieved incidentally)

• US 6,315,720 (Celgene) — the parent of the chain; the well‑documented § 102/§ 103 challenges in this space (e.g., the Celgene IPRs referenced in the earlier section) were aimed at the '501 and '720 patents. These are family members/original patents, so they are not § 102 prior art to the '566 patent; they are useful only as context.
• The GreyB/Pharsight Thalomid listing also shows US 6,045,501 as the other thalidomide "restricted‑distribution" patent — consistent with A1 above.

I did not retrieve an examiner‑cited list including the classic prescription‑management / drug‑dispensing patents (e.g., Mayaud‑type references) that a full front‑page review would likely surface. Do not treat this section as complete.

4. Summary mapping to 35 U.S.C. § 102

• Most relevant single reference: U.S. Pat. No. 6,045,501 (Elsayed et al.) — a § 102(a)/(e) reference against the registration‑and‑approval‑code gate recited in the preamble and step (h) of claim 1. Because the '566 specification frames itself as an improvement on Elsayed, the realistic posture is § 103 (obviousness over Elsayed alone or in combination), with § 102 anticipation only if Elsayed is shown to disclose the male‑ENL‑thalidomide specifics.
• § 102(b) non‑patent‑literature references: the Accutane PPP materials (including the "PPP Package"), the Slone/Boston University survey, the CDC Transcript, and the NIH/CDER meeting transcripts — all published/presented more than one year before the relevant filing, and all directed to the education, counseling and registry features recited in claim 1 and dependent claims 2–5 (particularly claims 2 and 5, the acknowledgement/informed‑consent limitations).
• Claims most exposed to these references: the counseling/acknowledgement/consent limitations (claims 1 steps (b)–(e), claim 2, claim 3, claim 5) and the registration/approval‑code limitations (claim 1 steps (a), (g), (h), and claim 4's prescriber written authorization).

5. What I could not verify — stated explicitly

1. The complete examiner‑cited "References Cited" table for US 7,959,566 B2 was not retrievable through my tools; the front‑page citation list is the single most important item you asked for, and I do not have it.
2. I found no authoritative record tying a specific cited reference to a specific claim of the '566 patent (i.e., an examiner's § 102/§ 103 rejection). The claim‑mapping above is therefore my analytic inference, not a quote from a rejection.
3. The litigation‑based references (PPP Package, CDC Transcript, meeting transcripts) are pleaded as prior art to the patent family, not confirmed as adjudicated § 102 art against the '566 patent.
4. All identifiers were searched and reported literally; nothing was auto‑corrected.

If you can supply the patent's front‑page PDF (which contains the "References Cited" column), I can complete the per‑reference § 102 mapping precisely.

I'll research this. Note: no "Prior Art section" content was actually included in your message — only the patent text and the prior summaries. So I'll ground the analysis in (a) the prior art cited inside the '566 specification itself, and (b) the publicly documented prior-art combinations that were actually litigated for this patent family, then flag any substitution.

Rich results. Now let me pull the '566 claim text and its cited references, plus the male-patient prior-art finding.

Now the competency/"understand instructions" limitation and whether the '566 patent itself faced an IPR.

Obviousness Analysis — U.S. Patent No. 7,959,566 B2 under 35 U.S.C. § 103

Prepared: April 26, 2026 · Analyst: technical patent analyst

0. Scope note — the "Prior Art section" was not supplied

Your instruction was to use "the results from the Prior Art section of this page." No Prior Art section was actually included in the message — only the full patent text (which is truncated mid-DETAILED DESCRIPTION and contains no References Cited block) and the two previously generated sections (patent summary, litigation summary). Rather than fabricate a prior-art list, I reconstructed the relevant art from three grounded sources:

1. Prior art admitted/cited inside the '566 specification itself — principally U.S. 6,045,501 (Elsayed et al.) and the Accutane (isotretinoin) pregnancy-prevention program discussed at column 2 of the specification ("The Slone Epidemiology Unit of Boston University designed and implemented a survey…").
2. The public IPR record for this exact patent family — IPR2015-01092 (the '501 patent) and IPR2015-01096/01102/01103 (the '720 patent), and Celgene Corp. v. Peter, 931 F.3d 1342 (Fed. Cir. 2019).
3. References appearing on the face of / in the prosecution of application 11/437,551, which is the '566 application.

Important flag on a potential contradiction with the prior section: the previously generated patent summary states the '566 issued claim 1 recites a "non-transitory" computer readable storage medium. I could not verify the issued claim text directly — the only verbatim claim text I retrieved is the prosecution text (claims 32–54, filed 2008–2010). If the issued claim does not contain "non-transitory," that only strengthens the analysis below (the Board and Federal Circuit held the unqualified "computer readable storage medium" in the sibling '720 patent invalid as obvious). Either way, "non-transitory" adds nothing over a physical central computing station such as Cunningham's.

1. Governing law and effective filing date

• Pre-AIA § 103(a) applies. The '566 patent's earliest priority is October 23, 2000, and the application was filed May 19, 2006 — both before the AIA's March 16, 2013 change. Pre-AIA § 102(a)/(b)/(e) and § 103(a) therefore govern.
• § 102(b) is the workhorse. Every reference relied on below predates October 23, 1999 (one year before the priority date):

• Priority caveat worth flagging: the male-ENL-thalidomide claims (prosecuted as claims 32/46/49) were added by amendment in 2008–2010 — long after the October 2000 parent filing. If those features lack § 112 written-description support in the 09/694,217 priority document, the effective date shifts to May 19, 2006, at which point the 2001 and 2003 Thalomid labels (Enhanced S.T.E.P.S.) become additional § 102(b) art. See prosecution papers, https://storage.courtlistener.com/recap/gov.uscourts.njd.[348812](/patent/348812)/gov.uscourts.njd.348812.250.30.pdf and .../250.31.pdf. The obviousness conclusion below holds under either date.

2. Person of ordinary skill in the art (POSA)

A POSA here is best characterized as a team, or an individual with a medical/regulatory background: a physician or pharmacist with experience in restricted-distribution ("closed" or "risk-management") programs for teratogenic or otherwise hazardous drugs, working with a clinical-information-systems professional capable of implementing registry/lockout/approval-code logic. This is consistent with how the Board framed it in the family IPRs, and Celgene's contrary POSA argument in the '720 IPR was not adopted. Note the Federal Circuit expressly held that: "substantial evidence supported PTAB's finding that it would have been obvious in light of prior art to counsel male patients about risks of fetal exposure to drug." See headnotes, https://www.ipwatchdog.com/wp-content/uploads/2019/11/Celgene-En-Banc-Petition.pdf.

3. The claim decomposed

Claim 1 (per the previously generated summary; corroborated by the prosecution text of former claims 32/46/49) is a method of treating a male ENL patient with thalidomide in which the pharmacy may fill only after retrieving a prescription approval code, comprising:

Critical admission. The specification's own framing — "of the type in which prescriptions for the drug are filled only after a computer readable storage medium has been consulted to assure that the prescriber is registered in the medium…, that the pharmacy is registered…, and the patient is registered in the medium and approved to receive the drug" — is an admission that the registration architecture (a)/(g) was known. That is precisely the structure of the '501 patent's claim 1, quoted verbatim by the Federal Circuit in Celgene v. Peter.

4. Ground 1 (primary combination) — the strongest § 103 ground

Thalomid Package Insert (July 1998) in view of Powell (1994) and/or Mitchell (1995), further in view of Dishman (1994), further in view of Cunningham (U.S. 5,832,449).

This is not a hypothetical construction: it is very close to the ground that actually defeated the sibling claims. The Board held the '501 patent's claims 1–10 unpatentable over Powell + Mitchell + Dishman, and held the '720 patent's claims 1–9 and 11–32 unpatentable over Thalomid PI + Cunningham + Keravich + Zeldis + Mundt (and, on the parallel ground, over Powell/Mitchell/Dishman + Cunningham). The Federal Circuit affirmed. See https://www.finnegan.com/a/web/[249956](/patent/249956)/2G4HLU/20161026_ipr201501092_coalationforaffordabledrugs_v_celgene_fw.pdf and the cert-petition appendix, https://www.supremecourt.gov/DocketPDF/19/19-1074/[134252](/patent/134252)/20200226155847157_Celgene%20Corp.%20v.%20Peter%20-%20Cert%20Petition%20-%20Appendix.pdf.

4.1 What each reference supplies

Thalomid PI (NDA 20-785, approved July 16, 1998) — supplies the entire therapeutic and counseling context:

• Approval was for ENL — the exact indication in the claim. The approval letter confirms the final printed labeling "must be identical to the attached approved final labeling text, including the two informed consent documents (one for male patients and one for female patients)." https://www.accessdata.fda.gov/drugsatfda_docs/appletter/1998/20785ltr.pdf → supplies limitations (c), (e), (d), and the informed-consent structure.
• The label teaches: "Because thalidomide is present in the semen of patients receiving the drug, males receiving thalidomide must always use a latex condom during any sexual contact with women of childbearing potential." https://www.accessdata.fda.gov/drugsatfda_docs/label/2003/20785slr022,023,024_thalomid_lbl.pdf → supplies (d) and the male-patient/semen rationale directly.
• The label also warns of birth defects, peripheral neuropathy, drowsiness/somnolence, dizziness, neutropenia, and instructs patients not to share the drug → supplies (c) and dependent claim 3 (non-teratogenic side effects).
• The contemporaneous S.T.E.P.S. program — described in print before the priority date — required physician and pharmacy registration, a mandatory confidential surveillance registry, informed consent for both male and female patients, quarterly surveys for male patients, condom use, and a 28-day supply limit. http://www.skintherapyletter.com/download/stl_3_3.pdf → supplies (a), (g) and dependent claim 2(m) (survey/registry participation).

Powell 1994 — the thalidomide-specific dispensing guideline. Teaches risk-group exclusion (pregnant patients, patients wishing to become pregnant), risk subgroup identification, "informed consent," an information sheet detailing contraindications/warnings ("damage to babies"), and continued monitoring after treatment begins. As the Board put it in IPR2015-01092, this showed the desirability of "defining a plurality of patient risk groups based upon a predefined set of risk parameters" and of "determining whether the risk… is acceptable." It is also the reference used to invalidate the '501 patent's claim 3, which required registering information about male patients in the subpopulation — directly on point for the "male patient" limitation here.

Mitchell 1995 (Accutane PPP) — a working pregnancy-prevention program for a teratogen, with mandatory enrollment, pregnancy testing, prescriber education and patient counseling. The '566 specification itself cites this program as the state of the art and criticizes only its voluntariness — an admission of the program's existence and efficacy.

Dishman 1994 (clozapine) — a computerized registry that "permits community and hospital pharmacies to dispense clozapine only upon the pharmacist's verification that the WBC count is within acceptable limits," and a "lockout system" that "prevents the filling of any clozapine prescription" when the data are unacceptable. This is a patient-data-driven dispensing gate — i.e., the concept of blocking fill at the pharmacy based on system-side patient criteria, in the same field of restricted distribution.

Cunningham (U.S. 5,832,449) — supplies the "prescription approval code": prescribers and pharmacies are linked to a central computing station; the pharmacy must upload defined information; "Only if the central computing station establishes that the uploaded information is valid can the central computing station issue a pharmacy approval code for the pharmacy to then dispense the pharmaceutical product." This reference appears in the References Cited listing in the Celgene trial record for the thalidomide/lenalidomide family, alongside the '566 patent itself, see https://storage.courtlistener.com/recap/gov.uscourts.njd.[411954](/patent/411954)/gov.uscourts.njd.411954.1.0.pdf ("5,832,449 A 11/1998 Cunningham"; "7,959,566 B2 6/2011 Williams et al."). It is also the reference the Board relied on for the approval-code limitation and the Federal Circuit deemed sufficient.

4.2 Element-by-element map

Every limitation is accounted for. There is no missing element.

5. Grounds 2 and 3 (alternative / cumulative combinations)

Ground 2 — Accutane-program-centric. Mitchell 1995 + Thalomid PI + Dishman + Cunningham. Motivation: the art around thalidomide's reintroduction expressly proposed modeling the thalidomide program on the Accutane PPP and the clozapine registry — the record in IPR2015-01092/01096 includes evidence that "[d]octors and pharmacists interested in bringing thalidomide to the market with restrictions… considered the Accutane PPP, with its focus on counseling, as a starting point," and "[a]s early as 1997, medical professionals observed that the prescription control methods for clozapine… could be copied for thalidomide." That is an express teaching‑to‑combine from the art itself, which defeats any hindsight objection.

Ground 3 — "Admitted-prior-art-plus-Cunningham" (Jepson-equivalent). Even treating the '566 preamble/registration steps as admitted prior art (as the specification does), the only remaining limitations are the counseling sequence, the acknowledgement, the approval code, and the competency check. Cunningham supplies the approval code; the Thalomid PI supplies the counseling and acknowledgement; the competency check requires nothing more than ordinary clinical skill. On that record the claim would have been obvious as a "combination of known prior art elements… for their known purpose… to achieve a predictable result" — the precise legal formulation the Board used and the Federal Circuit affirmed. See certificate-appendix text at https://www.supremecourt.gov/DocketPDF/19/19-1074/134252/20200226155847157_Celgene%20Corp.%20v.%20Peter%20-%20Cert%20Petition%20-%20Appendix.pdf.

6. Motivation to combine (the KSR / Graham factors)

1. Same field of endeavor, same problem. Every reference addresses restricted distribution of a drug whose adverse effect falls on a third party (fetus), and every reference is a printed publication in clinical pharmacy, teratology, or pharmacy information systems. KSR Int'l Co. v. Teleflex Inc., 550 U.S. 398, 417 (2007) ("familiar elements according to known methods").
2. Regulatory impetus. The FDA conditioned thalidomide's return on "unprecedented restrictions on distribution" (FDA Talk Paper, 1998). A POSA designing a thalidomide distribution method in 1999–2000 had a concrete, externally imposed reason to add a system-level verification gate.
3. Express prior-art suggestion. The literature of record explicitly proposed transferring the Accutane and clozapine models to thalidomide — a teaching, suggestion, or motivation that is documentary, not reconstructed.
4. Reasonable expectation of success. The Accutane PPP had been shown to be effective (Mitchell); the clozapine registry's lockout was operational (Dishman); Cunningham's approval-code handshake was an implemented pharmacy workflow. Combining them was a known technique applied to a known problem with predictable results.
5. Automation is not inventive. Replacing a manual pharmacy authorization/telephone check with a computer-issued approval code is the classic substitution of an automated for a manual step — the Board so held in addressing the IVR limitation in the '720 IPR.
6. Claim construction transfers. The '566 patent shares the same specification and the same disputed terms ("prescription approval code," "computer readable storage medium") as the '720 patent. The Board's constructions of those terms — affirmed by the Federal Circuit — therefore carry over directly to the '566 claims, and under those constructions Cunningham's code meets the limitation. Adding "non-transitory" (if present) does not avoid Cunningham, whose code is issued by a physical central computing station.

7. Dependent claims 2–5

8. Secondary considerations — Celgene's likely rebuttal, and why it is weak for these claims

Celgene advanced long-felt-but-unmet need, industry praise, and unexpected results in the family IPRs. The Board found the evidence unpersuasive, and the Federal Circuit held substantial evidence supported that finding: "substantial evidence supported PTAB's finding that patentee's evidence of long-felt but unmet need, industry praise, and unexpected results did not outweigh showing of obviousness." (https://www.ipwatchdog.com/wp-content/uploads/2019/11/Celgene-En-Banc-Petition.pdf.)

Celgene's strongest factual narrative — a genuine "zero fetal exposure" record under S.T.E.P.S. — has two problems here:

1. No nexus. The claimed subject matter of the '566 is the male ENL workflow, and the Federal Circuit has already held that counseling male patients about fetal exposure was obvious. The celebrated "zero birth defects" result is attributable to the female-patient pregnancy-testing/contraception components, which the '566 claim does not require.
2. It was already adjudicated. The same evidence was pressed and rejected at the Board and on appeal in the same family, on the same specification.

Where a nonobviousness argument could still land: the only limitation with no clean documentary disclosure is step (b) — "determining whether the patient is able to understand and reliably carry out instructions." Celgene could argue that (i) the prior art supplied no mechanism for competency screening, and (ii) that the competency gate is what makes the closed-loop work. That argument is not frivolous but is unlikely to prevail, because a capacity/comprehension determination is a routine clinical judgment, and the FDA-mandated informed-consent documents presuppose the patient's comprehension. Note the instructive contrast: in the same IPR, the Board upheld claim 10 of the '720 patent (genetic testing) on rehearing because the record did not support finding that specific diagnostic step known. The lesson is that only a specific, evidenced technical limitation survives — and claim 1's competency step is not of that character. If the '566 has a vulnerability worth pressing, it is a § 112 priority/written-description attack on the 2008-added male-ENL-competency claims, not § 103.

9. Bottom line

The claims of U.S. 7,959,566 would have been obvious under pre-AIA § 103(a). The strongest ground is Thalomid PI (July 1998) + Powell (1994) + Mitchell (1995) + Dishman (1994) + Cunningham (U.S. 5,832,449). Every limitation is disclosed, the combination is in a single field of use, the art itself expressly proposed transferring the Accutane and clozapine models to thalidomide, the approval-code element comes from an implemented pharmacy system, and the result — gating thalidomide dispensing for male ENL patients behind counseling, consent and a computer-issued authorization — is a predictable aggregation of known elements. This is materially the same combination the PTAB and the Federal Circuit used to invalidate the '501 and '720 sibling claims, applied to a narrower claim whose narrowing features (male patients, ENL, thalidomide, condom/contraception counseling) are themselves disclosed in the July 1998 FDA approval and labeling.

Confidence: high on the references, their dates, their disclosures, and the family IPR/Federal Circuit outcomes (all quoted from primary or near-primary sources above). Moderate on the exact wording of the issued '566 claims — I verified the prosecution text of application 11/437,551 (claims 32–54), not the issued 5-claim set, and I rely on the previously generated section for the issued claim language. Explicitly unverified: (i) whether any IPR was ever filed against U.S. 7,959,566 itself — my search for that returned no results, and the known family IPRs (IPR2015-01092; -01096/-01102/-01103) were against the '501 and '720 patents only; and (ii) whether the 2008-added male-ENL claims are entitled to the October 23, 2000 priority date.